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11. Introduction
1.1 Background
The Belgian pharmacologist and pharmaceutical chemist Paul Janssen developed 
fentanyl in 1960. It was at the time a revolutionary compound with a potency much 
greater than that of the natural opioid morphine, and a significantly greater safety 
margin than other pharmaceutical synthetic opioids such as dextromoramide, meper-
idine and phenoperidine. Under Janssen’s leadership, a deeper understanding of the 
structure/activity relationships led to the development of the very potent analgesics 
sufentanil, alfentanil, lofentanil and carfentanil, which could also be used for anaes-
thesia [1]. These drugs have been successfully used clinically for over fifty years, 
and have made possible complex surgeries and the successful management of 
chronic pain for millions of patients worldwide. Fentanyl, together with codeine, 
methadone and morphine are four opioid analgesics on the World Health Organiza-
tion’s (WHO) List of Essential Medicines [2].
In California, United States in 1979, a series of deaths occurred in people who 
injected drugs that were subsequently attributed to an analogue of fentanyl, alpha-
methylfentanyl. Initially discovered and patented by Janssen [3], alpha- methylfentanyl 
had neither been evaluated in humans for safety or efficacy, nor approved as a 
pharmaceutical drug [4,5]. This was the first recorded instance of a completely 
novel clandestinely synthesized opioid, and earned the sobriquet “designer drug”. 
Through the early 1980s alpha-methylfentanyl was quickly joined by a series of 
other  fentanyl analogues including: para-fluorofentanyl, 3-methylfentanyl, beta- 
hydroxyfentanyl, and a number of others that were identified in deaths in the west 
coast of the United States. 
Subsequently, the use of fentanyl itself became widespread due to its availability 
worldwide in injectable, sublingual and transdermal forms, and it also became sub-
ject to diversion and abuse. There were isolated cases of fentanyl and its analogues 
being mixed with heroin in the street drug supply, such as in the “Tango and Cash” 
product sold in New York City in 1991, resulting in deaths and hospitalizations. 
Fentanyl was also recognized as a problem in Europe in 2012 [6,7]. At the begin-
ning of 2014, the availability of fentanyl in the United States had started to increase 
exponentially [8], with crime laboratories reporting more than 4,500 fentanyl cases 
in 2014 and over 14,400 in 2015. Around the same time, a group of fentanyl new 
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psychoactive substances (NPS) began to appear in the street drug market, beginning 
with acetylfentanyl, and butyrylfentanyl. By 2017, 15 fentanyl analogues and two 
precursor chemicals had been placed under international control and more than 
20 individual substances had been detected in deaths. They have been routinely 
detected in drug markets in Europe and North America, and several more have been 
encountered in smaller, more isolated incidents, along with other non-morphine or 
fentanyl-related opioid receptor agonists. Because of their potency and toxicity in 
overdose, the ease with which they can be manufactured and distributed, and their 
proliferation in international markets, this manual has been prepared to assist public 
health, forensic, and clinical laboratories with the identification, analysis and quan-
tification of novel fentanyl analogues found in overdoses, poisonings and death 
investigation casework. 
1.2 Purpose and use of the manual
The present manual is one in a series of similar UNODC publications dealing with 
the identification and analysis of various types of drugs under international control. 
These manuals are the outcome of a programme pursued by UNODC since the 
early 1980s, aimed at the harmonization and establishment of recommended meth-
ods of analysis for national drug analysis laboratories. The present manual is the 
first to deal specifically with the analysis of the growing class of fentanyl-related 
compounds and focuses on testing in biological tissues and fluids, to assist with 
investigation of fentanyl-related poisonings and deaths. Many of these analytical 
considerations also apply to analysis of seized drugs. The first part of the manual 
discusses the pharmacology and toxicology of fentanyl and its analogues, which is 
an especially important consideration for this drug class, because the potency of 
the substances can vary widely. This is followed by a discussion of validated ana-
lytical methodologies, using different analytical techniques and instrumental modes 
of operation. 
In line with the overall objective of this series of UNODC publications, this manual 
suggests approaches that may assist drug analysts in the selection of methods appro-
priate to the sample under examination, and the range of technologies and resources 
that might be available in their laboratories. Therefore, the methods described here 
should be understood as practical guidance, that is, minor modifications to suit local 
circumstances should normally not change the validity of the results. The choice of 
the methodology and approach to analysis, as well as the decision as to whether or 
not additional methods are required, remain with the analyst and may also be depend-
ent on the availability of appropriate instrumentation and the level of legally accept-
able proof in the jurisdiction within which the analyst works. The reader should be 
aware that there are a number of other methods, including those published in forensic 
science literature, which may also produce acceptable results. However, any new 
method that is about to be used in a laboratory must be validated and/or verified 
prior to routine use. Attention is also drawn to the importance of the availability of 
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reference materials and literature on drugs of abuse and analytical techniques. More-
over, the analyst must of necessity keep abreast of current trends in drug analysis, 
consistently following current analytical and forensic science literature. UNODC 
Laboratory and Scientific Section welcomes observations on the contents and useful-
ness of the present manual. Comments and suggestions may be addressed to: 
 Laboratory and Scientific Section, United Nations Office on Drugs and Crime, 
Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria. Fax: (+43-1) 
26060-5967. E-mail: Lab@unodc.org. All manuals, as well as guidelines and other 
scientific-technical publications may be requested by contacting the address above 
or can be accessed online at https://www.unodc.org/unodc/en/scientists/index.html.

52. General aspects
2.1 Definition of fentanyl and analogues
Table 1 includes a list of fentanyl and its analogues that are under international 
control and a secondary list of fentanyl-related new psychoactive substances that 
have been reported to the UNODC Early Warning Advisory, as well as newly emerg-
ing fentanyls recently seen in forensic casework in several jurisdictions.
Table 1.  List of fentanyl substances under international control and controlled 
fentanyl analogues reported to the UNODC Early Warning Advisory 
on New Psychoactive Substances as of September 2017.
Name: Acetyl-alpha-methylfentanyl
Alternate name: N-phenyl N-(1-(1-phenylpropan-
2-yl)piperidin-4-yl)acetamide
CAS no. 101860-00-8 
M.W. 336.48
Control: 1961, Schedule I/IV 
Name: Acetylfentanyl
Alternate name: N-[1-(2-Phenylethyl) 
-4-piperidyl]-N-phenylacetamide
CAS no. 3258-84-2 
M.W. 322.45
Control: 1961, Schedule I/IV
Name: Alfentanil
Alternate name: N-(1-(2-(4-ethyl-5-oxo-4,5- 
dihydro-1H-tetrazol-1-yl)ethyl)-4-(methoxymethyl)
piperidin-4-yl)-N-phenylpropionamide
CAS no. 71195-58-9 
M.W. 416.53 
Control: 1961, Schedule I 
O
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Name: alpha-Methylfentanyl
Alternate name: N-phenyl-N-(1-(1-phenylpropan-
2-yl)piperidin-4-yl)propionamide
CAS no. 79704-88-4
M.W. 350.51 
Control: 1961 Schedule I/IV 
Name: alpha-Methylthiofentanyl
Alternate name: N-phenyl-N-(1-(1-(thiophen-2-yl)
propan-2-yl)piperidin-4-yl)propionamide
CAS no. 103963-66-2
M.W. 356.53 
Control: 1961 Schedule I/IV 
Name: beta-Hydroxyfentanyl
Alternate name: N-(1-(2-hydroxy-2-phenylethyl)
piperidin-4-yl)-N-phenylpropionamide
CAS no. 78995-10-5
M.W. 352. 48 
Control: 1961 Schedule I/IV 
Name: beta-Hydroxy-3-methylfentanyl
Alternate name: N-(1-(2-hydroxy-2-phenylethyl)-3- 
methylpiperidin-4-yl)-N-phenylpropionamide
CAS no. 78995-14-9
M.W. 366.51
Control: 1961 Schedule I/IV 
Name: Butyrylfentanyl
Alternate name: 
N-(1-phenethylpiperidin-4-yl)-N-phenylbutyra-
mide
CAS no. 1169-70-6 
M.W. 350.51 
Control: 1961 Schedule I
Name: Fentanyl
Alternate name: 
N-(1-phenethylpiperidin-4-yl)-N-phenylpropiona-
mide
CAS no. 437-38-7
M.W. 336.48 
Control: 1961 Schedule I 
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Name: 3-Methylfentanyl
Alternate name: N-(3-methyl-1-phenethylpiperidin-4-yl)- 
N-phenylpropionamide
CAS no. 42045-86-3
M.W. 350.51 
Control: 1961 Schedule I/IV 
Name: 3-Methylthiofentanyl
Alternate name: N-(3-methyl-1-(2-(thiophen-2-yl)
ethyl)piperidin-4-yl)-N-phenylpropionamide
CAS no. 86052-04-2
M.W. 356.53 
Control: 1961, Schedule I/IV 
Name: para-Fluorofentanyl
Alternate name: N-(4-fluorophenyl)-N-
(1-phenethylpiperidin-4-yl)propionamide
CAS no. 1189887-65-7 
M.W. 354.47 
Control: 1961 Schedule I/IV 
Name: Remifentanil
Alternate name: methyl 1-(3-methoxy-
3-oxopropyl)-4-(N-phenylpropionamido)
piperidine-4-carboxylate
CAS no. 132875-61-7
M.W. 376.45
Control: 1961 Schedule I 
Name: Sufentanil
Alternate name: N-(4-(methoxymethyl)-1-(2-
(thiophen-2-yl)ethyl)
piperidin-4-yl)-N-phenylpropionamide
CAS no. 56030-54-7
M.W. 386.55 
Control: 1961 Schedule I 
Name: Thiofentanyl
Alternate name: N-phenyl-N-(1-(2-(thiophen-2-yl)
ethyl)piperidin-4-yl)propionamide
CAS no. 1165-22-6
M.W. 342.50 
Control: 1961 Schedule I/IV 
O
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Substances not under international control as of September 2017
Name: Acrylfentanyl
Alternate name: 
N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide
CAS no. 82003-75-6 
M.W. 334.46
Name: Benzoylfentanyl 
Alternate name: 
N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide
CAS no. N/A
M.W. 384.52
Name: Benzylfentanyl
Alternate name: 
N-(1-benzylpiperidin-4-yl)-N-phenylpropionamide
CAS no. 1474-02-8
M.W. 322.45
Name: beta-Hydroxythiofentanyl
Alternate name: N-(1-(2-hydroxy-2-(thiophen-
2-yl)ethyl)piperidin-4-yl)-N-phenylpropionamide
CAS no. 1474-34-6 
M.W. 358.50 
Name: Carfentanil
Alternate name: methyl 1-phenethyl-4-(N-phe-
nylpropionamido)piperidine-4-carboxylate
CAS no. 59708-52-0
M.W. 394.52 
Name: Cyclopropylfentanyl
Alternate name: 
N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopro-
panecarboxamide
CAS no. N/A 
M.W. 348.49 
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Name: Despropionyl-2-fluorofentanyl
Alternate name: 
N-(2-fluorophenyl)-1-phenethylpiperidin-4-amine
CAS no. 864422-91-3
M.W. 298.41
Name: Despropionylfentanyl 
(4-anilino-N-phenethylpiperidine)
Alternate name: 
1-phenethyl-N-phenylpiperidin-4-amine
CAS no. 21409-26-7
M.W. 280.42 
Name: 2-Furanylfentanyl
Alternate name: N-(1-phenethylpiperidin-4-yl)-N- 
phenylfuran-2-carboxamide
CAS no. 101345-66-8
M.W. 374.48 
Name: 2-Furanylfentanyl ortho-2-isopropylphenyl 
analogue 
Alternate name: N-(2-isopropylphenyl)-N-
(1-phenethylpiperidin-4-yl)furan-2-carboxamide
CAS no. N/A 
M.W. 416.57
Name: 2-Furanylfentanyl ortho-2-methoxyphenyl 
analogue 
Alternate name: N-(2-methoxyphenyl)-N-
(1-phenethylpiperidin-4-yl)furan-2-carboxamide 
CAS no. N/A
M.W. 404.51
Name: 2-Furanylfentanyl ortho-2-methylphenyl 
analogue 
Alternate name: N-(1-phenethylpiperidin-4-yl)-N-
(o-tolyl)furan-2-carboxamide
CAS no. N/A 
M.W. 388.51
N
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Name: 2-Furanylfentanyl para-chlorophenyl 
analogue
Alternate name: N-(4-chlorophenyl)-N-
(1-phenethylpiperidin-4-yl)furan-2-carboxamide
CAS no. N/A
M.W. 408.93
Name: Isobutyrylfentanyl
Alternate name: 
N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyra-
mide
CAS no. 117332-90-8 (HCl) 
M.W. 350.51 
Name: Isobutyryl-F-fentanyl N-benzyl analogue
Alternate name: N-(1-benzylpiperidin-4-yl)-N-
(4-fluorophenyl)isobutyramide
CAS no. N/A 
M.W. 354.47 
Name: ortho-Fluorofentanyl
Alternate name: N-(2-fluorophenyl)-N-
(1-phenethylpiperidin-4-yl)propionamide
CAS no. N/A 
M.W. 354.47 
Name: para-Chloroisobutyrylfentanyl
Alternate name: N-(4-chlorophenyl)-N-
(1-phenethylpiperidin-4-yl)isobutyramide
CAS no. N/A
M.W. 384.95 
Name: para-Fluorobutyrylfentanyl
Alternate name: N-(4-fluorophenyl)-N-
(1-phenethylpiperidin-4-yl)butyramide
CAS no. 244195-31-1
M.W. 368.50 
N
O N
O
Cl
O
N
N
O
N
N
F
O
N
N
F
O
N
N
Cl
O
N
N
F
Identification and analysis of fentanyl and its analogues in biological specimens 11
Name: para-Fluoroisobutyrylfentanyl
Alternate name: N-(4-fluorophenyl)-N-
(1-phenethylpiperidin-4-yl)isobutyramide
CAS no. N/A
M.W. 368.50 
Name: para-Methoxybutyrylfentanyl
Alternate name: N-(4-methoxyphenyl)-N-
(1-phenethylpiperidin-4-yl)butyramide
CAS no. N/A
M.W. 380.53 
Name: para-Methylphenethylacetylfentanyl 
Alternate name: N-(1-(4-methylphenethyl)
piperidin-4-yl)-N-phenylacetamide
CAS no. 1071703-95-1 (HCl) 
M.W. 336.48 
Name: Tetrahydrofuranylfentanyl 
Alternate name: 
N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahy-
drofuran-2-carboxamide
CAS no. N/A
M.W. 378.52 
Name: Valerylfentanyl
Alternate name: 
N-(1-phenethylpiperidin-4-yl)-N-phenylpentana-
mide
CAS no. 122882-90-0
M.W. 364.53 
2.2 Nomenclature
The most formal system for naming chemical compounds follows nomenclature rules 
designated by the International Union of Pure and Applied Chemistry (IUPAC). How-
ever, the spelling and identity of substituent placement may vary depending on 
accepted practices, which may vary from country to country, leading to confusion 
regarding analyte identity. The fentanyl analogues have generic endings of yr-, yrl-, 
and oyl-, which are used interchangeably. Occasionally, alternative names arise from 
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multiple numerical conventions, such as valerylfentanyl, which is also known as 
 pentanoyl or pentanylfentanyl. Arene substitution pinpoints the position of substituents 
other than hydrogen in relation to each other on an aromatic hydrocarbon; ortho-, 
meta-, and para- and 2-, 3-, and 4- refer to the same placement, respectively, of those 
substituents (for example, 2-fluorofentanyl is ortho-fluorofentanyl). For consistency, 
this manual uses ortho-, meta- and para- designations. Esoteric notations include 
Greek symbols that can either be represented as the symbol or its name (for example, 
alpha- methylfentanyl = α-methylfentanyl). For consistency, this manual spells out the 
“alpha” and “beta” notations. 
2.3  Fentanyl products in pharmaceutical form 
and in combination with other substances
Pharmaceutical preparations of fentanyl are currently available as oral transmucosal 
lozenges, effervescent buccal tablets, sublingual tablets and sprays, nasal sprays, 
transdermal patches and injectable formulations [9]. Brand names for fentanyl 
include Actiq® (lozenge), Duragesic® (transdermal patch), Fentora™ (buccal tab-
let), Abstral® (sublingual tablet), Subsys™ (sublingual spray), Sublimaze® (injec-
tion), Lazanda® (nasal spray), and Ionsys™ (transdermal device). Sufentanil, and 
carfentanil brand names are Sufenta® and Wildnil™, respectively and brand names 
for alfentanil include Alfenta® and Rapifen®.
The popularity of fentanyl progressed beyond the use/abuse of pharmaceutical prepa-
rations, to the abuse of illicitly manufactured fentanyl, and eventually resulted in 
the proliferation of fentanyl analogues. Fentanyl and its analogues are typically seen 
in powder form, which can be used as is or mixed with another substance and then 
smoked or taken by the intranasal or intravenous route. They can also be pressed 
into tablets, often as counterfeit forms of other opioid pharmaceuticals (for example, 
 hydrocodone or morphine pills), or other drug classes (alprazolam tablets), or mixed 
into an intranasal spray [9–12]. The abuse of fentanyl and its analogues is popular 
due to its potent narcotic analgesic effects. These substances may act as a substitute 
for, or even enhance the effect of heroin and other natural and/or semi-synthetic 
opioids. It has been estimated that 41 per cent of the approximately 7,100 heroin-
related deaths in the United States between 2012 and 2014 involved fentanyl [13]. 
A number of countries, including Canada, Sweden, Estonia, Germany, the United 
Kingdom, Finland and Greece have reported almost 1,500 fentanyl-related fatalities 
between 2005 and 2014 [6,14,15]. In March 2015, the United States Drug Enforce-
ment Administration (DEA) issued a warning of fentanyl-laced heroin [16], and a 
number of other regions in the United States reported increases in illicit fentanyl-
related deaths [17–22].
One of the challenges of developing validated methods for the analysis and identifica-
tion of fentanyl and its analogues in such a rapidly changing and dynamic market is 
that analytical reference materials may often not be commercially available. To assist 
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the work of analysts, there are a number of online resources and databases (refer to 
table 2), which may contain reference mass spectra and other analytical data to  support 
the identification of novel and emerging fentanyl analogues. 
Table 2. Selection of online mass spectral and drug resources
UNODC https://www.unodc.org/LSS/Home/NPS
SWGDRUG http://swgdrug.org/
Southern Association of Forensic Scientists
http://forendex.safs1966.org/index.php/
home/index
European Project Response to Challenges 
in Forensic Drug Analyses
http://www.policija.si/apps/nfl_response_
web/seznam.php
Cayman Chemicals https://www.caymanchem.com/Home
Spectral Database for Organic Compounds 
SDBS
http://sdbs.db.aist.go.jp/sdbs/cgi-bin/
direct_frame_top.cgi
NPS Data Hub https://www.nps-datahub.com/
Designer Drugs Online MS Database https://db12.designer-drugs.de/login.pl
New Synthetic Drug Database http://nsddb.eu/
Data Search System for New Psychoactive 
Substances
http://npsdb.nihs.go.jp/Search/Default_e.
aspx
Mass Bank http://www.massbank.jp/?lang=en
Pubchem https://pubchem.ncbi.nlm.nih.gov/
Russian drug database
http://www.aipsin.com/article/aipsin/ips/
drugs/mass_spectra/msdb_description.pdf
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3.  Safety aspects of handling 
fentanyl exhibits
3.1 Good laboratory practice
Laboratory policies should be put into place to ensure safe work environments. In 
addition, laboratories should have the facility and protocols in place to perform the 
drug testing service(s) offered. The handling of biological materials exposes person-
nel to infection hazards from, among others, hepatitis and HIV; all personnel should 
therefore take the necessary precautions and adhere to safety procedures such as 
wearing gloves and other protective clothing. See Section VI. Laboratory accom-
modation, environment and safety in the Recommended Guidelines for Quality 
Assurance and Good Laboratory Practices, for additional recommendations [23].
The risk of clinically significant exposure of fentanyl and its analogues to emergency 
responders is extremely low, as incidental dermal absorption resulting in opioid toxicity 
is unlikely. The American College of Medical Toxicology (ACMT) and American 
Academy of Clinical Toxicology (AACT) advise that the use of basic personal protec-
tive equipment (PPE), such as nitrile gloves and a N95 respirator, are sufficient protec-
tion to avoid exposure to fentanyls either by dermal exposure or inhalation [24]. 
Availability and use of naloxone in analytical facilities
Emergency personnel and other professionals who may encounter fentanyl or 
 fentanyl analogues should be trained to recognize the symptoms of opioid intoxica-
tion, such as depressed respiratory function, confusion, and loss of alertness [24]. 
In addition, these professionals should have ready access to naloxone (for example, 
Narcan®), a medication used to block the effects of opioids, as well as training for 
its administration.
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4.  Pharmacology and toxicology of 
fentanyl and its analogues
4.1 Overview
Fentanyl, a potent narcotic analgesic, was developed in 1960. It is used in the treat-
ment of breakthrough cancer pain and other chronic pain, and in surgical anaesthesia. 
Fentanyl activates the same receptors as morphine, and is therefore classified as an 
opioid. Fentanyl belongs to a family of drugs based on a phenylethylpiperidine 
backbone, and possesses multiple sites for the addition or substitution of various 
chemical functional groups to produce subfamilies of compounds with similar or 
even higher analgesic or toxic effect.
Fentanyl and its analogues are characterized by potencies typically higher than that 
of morphine—up to several thousand times in the case of carfentanil or remifentanil, 
but typically of the order of ten to five hundred times morphine’s potency. They 
typically have a short duration of action, rapid onset of effect, high lipid solubility, 
few cardiovascular risks, and in contrast to morphine, low histamine release [25]. 
Pharmaceutical fentanyls are known to have a significant first pass effect, being rapidly 
metabolized in the liver. Subsequently, these are not administered therapeutically by 
the enteric route but instead by transmucosal methods, such as sublingual or buccal 
routes (lozenge, “lollipop”, or spray), in the management of breakthrough pain. For 
the treatment of chronic pain, fentanyl is administered by a transdermal patch. For 
surgical use and anaesthesia, fentanyls are administered by intramuscular or intrathecal 
methods as a nerve block, or by intravenous methods [26]. Pharmaceutical prepara-
tions of fentanyl have been diverted for abuse, with users applying multiple patches, 
or extracting, chewing, or smoking gel reservoirs from fentanyl patches [27–31]. 
Other pharmaceutical fentanyls (alfentanil, remifentanil, sufentanil, and carfentanil—
the latter approved only for veterinary use) only have applications in surgical anaes-
thesia as a result of their potency, and have historically been less subject to diversion 
and abuse [32]. Starting in the 1980s there have been incidents of clandestine and 
illicit synthesis of analogues of fentanyl. Some of these are taken directly from the 
Janssen patents of the 1960s and thereafter, but others are completely novel and 
have not previously been described. For those novel drugs, little is known in terms 
of strength of receptor binding or analgesic response in animals or man, and they 
represent a significant threat to public health and safety.
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4.2 Mechanism of action and toxicity
The pharmacological activity of fentanyl and its analogues is due to their activation 
of the opioid receptors, with primary activity resulting from activation of the mu 
receptor, which is the main receptor sub-type involved in pain signaling [33]. Besides 
their analgesic properties, mu-opioid receptor agonists cause pupillary constriction, 
constipation, decreased consciousness, euphoria and dose-dependent respiratory 
depression, which can lead to death. The euphoric effects of opioid agonists can 
lead to habituation and dependence. The delta-opioid receptors also contribute to 
analgesia, as well as sedation, impairment of cognition, depressed mood, and motor 
incoordination and impairment, while the kappa-opioid receptor mediates pain sensa-
tion, sedation, cognitive impairment, effects on mood, diuresis, and temperature 
control. Opioids with significant kappa receptor agonist binding also cause halluci-
natory or dissociative effects. Overall, the typical side effect profile of opioid agonist 
use includes respiratory depression, sedation, sleepiness, dizziness, nausea, vomiting, 
fatigue, headache and constipation. Tolerance to the analgesic and euphoric effects 
of opioids develops quickly, with doses frequently requiring adjustment for effective 
pain management. Cessation of opioid agonist use leads to a withdrawal syndrome, 
characterized by drug craving, dysphoria, anxiety, insomnia, irregular heart rate, loss 
of appetite, diarrhoea, sweating, nausea and vomiting [34]. 
The main mechanism of fatal opioid overdose is respiratory depression, leading to 
pathological indicators such as froth in the airways, and cerebral and pulmonary 
oedema. A distended urinary bladder is often observed at autopsy in opioid-induced 
death. Fentanyl and its analogues have high potency compared to morphine. Poor 
control of dose, poly-drug use, and patterns of repeated use are most likely contribu-
tors to the high rates of overdose, respiratory depression and death associated with 
these drugs [35]. 
4.3  Relative potency of fentanyl and its 
analogues
Fentanyl and its analogues were originally developed as safer alternatives to 
 morphine, with fewer side effects. Fentanyl itself has been demonstrated to have an 
analgesic potency of 50-100 times that of morphine, but with a therapeutic index 
approximately five times higher. Besides those fentanyl analogues that have been 
approved for human use such as fentanyl, remifentanil, alfentanil and sufentanil, 
few other fentanyl analogues have been evaluated for pharmacokinetic parameters 
in humans, including potency, binding affinity to mu-, delta-, and kappa-opioid 
receptors, or receptor efficacy. Due to the multiple positions at which substitutions 
can be made to the fentanyl core structure, such as replacement of or substitution 
on the phenyl or piperidinyl rings, alteration of chain length or substitution on the 
alkyl chain, and halogenation on multiple sites, a very large number of permutations, 
and consequently fentanyl analogues, are possible. These structural changes can 
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dramatically affect the analgesic activity and potency of such compounds, in addi-
tion to altering their legal status. Table 3 summarizes the analgesic activity and 
potency relative to morphine for fentanyl and selected analogues. The median effec-
tive dose (ED
50
) is the amount of drug that produces a therapeutic response or 
desired effect in half of the test subjects.
Table 3.  Analgesic activity (ED50) and analgesic potency relative to morphine 
for specified fentanyl analogues
Compound
Analgesic activity  
ED50 (mg/kg)
Analgesic potency 
relative to morphine
Reference
Morphine 13.9 1 [36]
Butyrylfentanyl 0.047-0.220 7 [37]
Furanylfentanyl 0.02 7 [38]
Acetylfentanyl 0.021 16 [37]
para-Fluorofentanyl 0.021 16 [37]
alpha-Methylfentanyl 0.0058 56.9 [37]
Alfentanil 0.044 75 [32]
Acrylfentanyl 0.082 170 [36]
Remifentanil 0.73 220 [39]
Fentanyl 0.062 224 [36]
Sufentanil 0.00071 4520 [40]
(+) cis-3-Methylfentanyl 0.00058 5530 [40]
Carfentanil 0.00032 10030 [40]
Isobutyrylfentanyl 0.048-0.261 1.3-6.9 [37]
Note that many of these data are derived from a selection of non-human animal 
models with different endpoints for analgesia, thus accounting for differences in 
findings. In aggregate however, these data give some sense of the relative potency 
of a range of analogues. All of the fentanyl analogues for which information is 
available have stronger analgesic activity relative to morphine [41]. However, these 
pre-clinical studies do not provide insight into toxicity of the fentanyl analogues, 
such as degree of respiratory depression or unconsciousness, and should only be 
used for cumulative understanding of relative potency to morphine.
As demonstrated in table 3, all fentanyl analogues have greater analgesic potency 
than morphine, and some can be more potent than fentanyl itself. For example, (+) 
cis-and trans-3-methylfentanyl are approximately 7,000 and 1,000 times more potent 
than morphine respectively [42], and carfentanil has an analgesic potency of more 
than 10,000 times that of morphine in a mouse model [37]. These differences, which 
result in a greater demand for analytical sensitivity, have implications for the 
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detectability of these very potent drugs in toxicological specimens. Some traditional 
analytical techniques such as liquid chromatography with UV visible detection (LC/
UV) and gas chromatography with flame ionization detection (GC/FID) are unsuit-
able for fentanyl analysis.
The variability in potency and half-life also have an impact on medical intervention. 
For example, acrylfentanyl is more potent than fentanyl, with a longer duration of 
action [43]. Consequently, acrylfentanyl may require a longer period of symptomatic 
support in the emergency room, or repeated doses of naloxone.
4.4 Metabolism
Identification of known metabolites of drugs can help prolong the detection window. 
For many fentanyl analogues, their metabolites may only have been postulated in 
the literature and not yet confirmed in authentic casework. However, the prediction 
of metabolites using known metabolic pathways yields likely scenarios that may be 
helpful in adding to toxicological assays, if reference material permits. As noted 
earlier, fentanyl has a phenylethylpiperidine core in its structure, and since many of 
its analogues typically incorporate variations on this core, they follow the established 
metabolic pathways of fentanyl.
The major route of metabolism for fentanyl is N-dealkylation on the piperidine 
 nitrogen to norfentanyl, its primary inactive metabolite, with minor pathways  involving 
amide hydrolysis to despropionylfentanyl and alkyl hydroxylation to hydroxyfentanyl 
[44]. Other fentanyl analogues share these general pathways. The metabolism of 
3-methylfentanyl, studied in rats and with recombinant human isoenzymes, identified 
N-dealkylation to 3-methylnorfentanyl followed by hydroxylation of the alkyl and aryl 
moiety, and hydroxylation of the propanamide side chain, as the predominant pathways 
[45]. Acetylfentanyl is metabolized in humans  predominantly by hydroxylation on the 
phenyl moiety to hydroxyacetylfentanyl, with formation of noracetylfentanyl being a 
minor pathway [46]. Acrylfentanyl and para-fluoro- isobutyrylfentanyl are  predominantly 
metabolized by N-dealkylation, cleaving off the phenethyl moiety, mono-hydroxylation 
at the ethyl linkage and piperidine ring, as well as hydroxylation/methoxylation at the 
phenyl ring [47]. The major metabolites of furanylfentanyl were generated by amide 
hydrolysis and dihydrodiol formation [48]. For butyrylfentanyl, hydroxylation and 
carboxylation predominated while the nor-metabolite and desbutyryl metabolite were 
minor [49,50]. For carfentanil, N-dealkylation and mono-hydroxylation of the piperi-
dine ring were the predominant routes of metabolism [51]. Table 4 shows known 
metabolites of the major fentanyls and highlights those metabolites that are common 
to more than one drug.
Based on the above considerations, it is likely that other fentanyl analogues whose 
fate has not been studied, are similarly metabolized through the same phase I reac-
tions to their respective nor-metabolites via N-dealkylation on the piperidine ring, 
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and via other common metabolic pathways including hydroxylation, dihydroxylation, 
and carboxylation, often in combination with N-dealkylation. Hydroxylated metabo-
lites are frequently conjugated through phase II reactions, making hydrolysis of 
urine samples advisable prior to analysis [47]. Due to similar structures and shared 
metabolic pathways, the metabolism of many fentanyl variants can result in shared 
metabolites, which may complicate interpretation of toxicological data. For example, 
norfentanyl will be detected as a metabolic product of fentanyl, alpha- methylfentanyl, 
and beta-hydroxythiofentanyl [52,53]. The metabolism of both alfentanil and 
 sufentanil share the common N-desalkyl metabolite. 4-ANPP (4-anilino-N-phenethyl-
piperidine; despropionylfentanyl) is frequently detected in fentanyl-related cases and 
is both a precursor to the manufacturing of illicit fentanyl and its analogues [44], 
as well as a shared metabolite of several; therefore, it offers limited specificity in 
terms of identifying what substance was ingested.
Table 4. Key fentanyl analogues and their known and common metabolites
Common name/
abbreviation
Structure Metabolite
Acetyl-alpha- 
methylfentanyl
Acetylfentanyl
Acrylfentanyl
O
N
N
O
N
NH
Acetylnorfentanyl [47]
O
N
N
O
N
N
O
N
NH
Acrylnorfentanyl [47]
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Butyrylfentanyl
Carboxybutyrylfentanyl [50]
Hydroxybutyrylfentanyl [50]
Fentanyl
 
beta-
Hydroxythio-
fentanyl
alpha-Methyl-
fentanyl
O
N
N
O
N
N
O
OH
O
N
N
OH
O
N
N
O
N
NH
Norfentanyl [52,54]O
N
N
OH
S
O
N
N
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para- 
Fluoroisobutyryl-
fentanyl
para-Fluoroisobutyrylnorfentanyl 
[47]
2-Furanylfentanyl
3-Methyl fentanyl
Alfentanil
O
N
N
F
O
N
NH
F
O
N
N
O
O
N
N
O
HO
HO
Furanylfentanyldihydrodiol [47]
N
H
N
Amide hydrolysis of  
furanylfentanyl [47]
O
N
N
O
N
NH
3-Methylnorfentanyl [45]
O
N
N
N
O
N
NN
O
O
N
NH
O
Noralfentanil [55]
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Sufentanil
Carfentanil
Remifentanil
O
N
NO S
O
N
NH
O
O
Norcarfentanil [51]
O
N
N
O
O
O
N
N
O
O
O
O
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5.  Analysis of fentanyl and its 
analogues and their metabolites in 
biological specimens
5.1  Priority fentanyl-related analytes in 
analytical casework
The focus of this manual is on both currently available fentanyl analogues approved 
for human or veterinary use (fentanyl, sufentanil, alfentanil, remifentanil, and carfen-
tanil), and illicit clandestinely synthesized fentanyl analogues. As of September 2017, 
the list includes those fentanyl analogues that are under international control and other 
fentanyl analogues that have been reported to the UNODC Early Warning Advisory 
on New Psychoactive Substances, as well as newly emerging fentanyls recently seen 
in forensic casework (see table 1). 
5.2  General structural considerations for selecting 
analytical methods
The fentanyl molecule is composed of three main parts: a phenylalkyl moiety, a 
piperidinyl ring, and a propylalkylamide moiety. Numerous fentanyl analogues are 
produced by modifications made on the propylalkylamide moiety of fentanyl, by 
altering the chain length on the arylalkylpiperidinyl group, or substituting the aro-
matic substituent on the phenylalkyl moiety. Fentanyl is basic drug with a pKa of 
8.4. Other fentanyl analogues had reported pKas as follows: alfentanil 6.5, remifen-
tanil 7.1 and sufentanil 8.0. Extraction efficiency is greatest when the pH of the 
solution is at approximately ±2 units of the pKa, at which point the drug will be 
either completely ionized or unionized. In liquid-liquid extraction protocols, the 
unionized form of the drug will be readily extracted into an organic solvent, and 
in the case of fentanyl all of the drug would be expected to be in the unionized 
form at two pH units above the pKa (pH ~ 10.4). In solid phase extraction methods 
using cation exchange, the optimal pH range would be two units below the pKa 
(pH ~ 6.4), resulting in the drug being ionized and allowing it to bind to the sorbent 
and be retained. 
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Modification and substitution of the fentanyl core structure to yield other fentanyls 
has resulted in multiple isomers with the same molecular formula and exact mass, 
but which differ in the arrangement of atoms within the molecules. The challenge 
of isomer differentiation is that identification is not always possible based solely on 
mass spectral means, especially when standard reference materials are not available. 
Isomers produce the same molecular ion and often the same base peak, and frequently 
have similar fragmentation patterns. In order to distinguish isomers that do not have 
unique fragmentation, they must be resolved chromatographically or  differentiated 
using unique transitions, where they exist. 
5.3 Testing and analysis
 Sampling and sample types—specimens from living individuals/ deceased 
individuals
Blood/serum/plasma
In living subjects, whole blood is generally collected from the antecubital vein. 
Plasma is the liquid portion of the blood derived when all the blood cells are sepa-
rated from whole blood. Serum is the liquid portion of the blood collected after 
clotting and removal of the clot. Drug concentrations in blood reflect the amount 
of drug present at the time of collection. Many factors influence the degree to which 
the blood or serum plasma concentration reflects the effects on the individual, includ-
ing tolerance, postmortem redistribution, acute versus chronic use, and receptor 
activation. Whole blood specimens should be collected into a tube that contains 
both a preservative and anticoagulant (for example, sodium fluoride and potassium 
oxalate). The blood-to-plasma ratio for fentanyl is reported to be 0.8-1.0, and for 
norfentanyl 1.0-1.3. Additional blood-to-plasma ratios have been reported for alfen-
tanil (0.6) and sufentanil (0.6-0.7) [56]. Postmortem specimens will vary in quality 
and homogeneity depending on a number of factors. Ideally, femoral or peripheral 
blood is best sampled and analysed for forensic toxicology purposes. 
Urine
Urine, as a biological sample, can be used to demonstrate previous exposure or 
historical drug exposure. Typically, after absorption, drugs or drug metabolites are 
present in urine at higher concentrations than in the blood. In urine, the target 
analytes are often the metabolites of the parent drugs, which are often inactive. The 
higher concentrations of drugs in urine have the advantage of extending the period 
over which prior drug use can be detected. 
Additional specimens from deceased individuals
Tissues
Tissue specimens, such as brain, liver, kidney, or muscle tissue from near the site 
of injection, can be tested in postmortem investigations. In the absence of blood or 
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urine, such as occurs after putrefaction, tissues can often be used to detect and in 
some cases quantify a suspected drug. Liver is the optimal sample in the absence 
of blood or urine. Drug concentrations determined from tissue analysis are difficult 
to interpret. Prior to analysis, it is recommended that tissue samples are homogenized 
using established protocols. 
Vitreous humour
Vitreous humour, which is a gel-like substance behind the lens and in front of the retina 
of the eye, is another alternative specimen recommended for analysis in postmortem 
toxicology casework. Vitreous humour is an anatomically isolated site, making it less 
susceptible to putrefactive changes such as postmortem redistribution. Often only 2-3mL 
can be collected for analysis. Concentrations of drugs in vitreous humour are often 
similar to those in blood; however interpretation should be done with caution.
Stability and storage
Fentanyl has been demonstrated to be stable in plasma at room temperature for 6 hours 
and for 6 months at -20°C [57]. In fluoridated blood, fentanyl was stable for 1 week 
at room temperature [58]. In urine, fentanyl and norfentanyl were stable for 24 hours 
at room temperature or 4°C [59]. Acetylfentanyl, alfentanil, beta-hydroxythiofentanyl, 
butyrylfentanyl, carfentanil, fluorofentanyl, fluoroisobutyrylfentanyl furanylfentanyl, 
alpha-methylfentanyl, para-methylphenethylacetylfentanyl, para-methoxybutyrylfen-
tanyl, norfentanyl and valerylfentanyl, were all stable in sodium fluoride/potassium 
 oxalate preserved human blood for at least 30 days at room temperature, refrigerated 
or frozen. Acrylfentanyl was stable for only one day at room temperature, seven days 
refrigerated, or one month frozen. 4-Anilino-N-phenethylpiperidine (4-ANPP) was 
 stable for fourteen days at room temperature, and for thirty days refrigerated or frozen. 
Stability indicates losses of less than 20 per cent over the period specified [60]. Best 
practices for detection of fentanyl in toxicological specimens call for them to be stored 
refrigerated or frozen until the time of analysis.
Screening methods for fentanyls
Immunoassays 
Immunoassays are commonly used for preliminary screening of biological speci-
mens to presumptively identify the presence of drugs. Immunoassays provide a 
quick, cost-efficient and sensitive screening method that allows for automation and 
high throughput. The principle involves the binding of the target (antigen) to an 
antibody coupled with a colour change reaction for detection. Depending on the 
specificity of the antibody and the degree of homology of the related drugs, an 
immunoassay may or may not give a positive reaction with other drugs that are 
chemically related to the principal target. As reflected below, various immunoassays 
have limited cross-reactivity with many of the fentanyl analogues, and for others 
their cross-reactivity is unknown. Consequently, immunoassays cannot be used to 
28 Identification and analysis of fentanyl and its analogues in biological specimens
reliably rule out the presence of fentanyl analogues in any given case, and other 
more sensitive and specific chromatographic/mass spectrometric methods as 
described below should be considered.
Known cross-reactivity of fentanyl analogues on common immunoassay tests
Fentanyl and fentanyl analogue cross-reactivity in urine was described using an 
enzyme-linked immunosorbent assay (ELISA) developed by Janssen Life  Sciences. 
The nine analogues included in the study and their cross-reactivities at 2 ng/mL, 
were as follows: acetylfentanyl (111%), para-methylfentanyl (93%), para-fluoro-
fentanyl (87%), butyrylfentanyl (77%), (±) trans-3-methylfentanyl (50%), alpha-
methyl fentanyl (19%) and (±) cis-3-methylfentanyl (3%). Benzylfentanyl and 
alfentanil did not cross-react [61]. 
The cross-reactivity of fentanyl analogues has been evaluated using the Neogen® fen-
tanyl ELISA with the following results: Less than 1% cross-reactivity was noted for 
4-ANPP, beta-hydroxythiofentanyl and norfentanyl in blood and urine, with the excep-
tion of 1.4% cross-reactivity for beta-hydroxythiofentanyl in urine. Other  fentanyl 
 analogues showed some cross-reactivity in blood/urine respectively: acetylfentanyl 
(31%/55%), butyrylfentanyl (66%/78%) and furanylfentanyl (63%/106%) [62].  Fentanyl, 
para-fluorofentanyl, furanylfentanyl, butyrylfentanyl and 4-ANPP were  evaluated for 
cross-reactivity on fentanyl ELISA and enzyme multiple immunoassay technique (EMIT) 
kits. Cross-reactivities in phosphate buffered saline on the ELISA kit, and in urine on 
the EMIT kit, respectively were butyrylfentanyl (90%/88%),  furanylfentanyl (77%/74%) 
and para-fluorofentanyl (47%/61%). 
5.4 Sample preparation
The following examples illustrate typical approaches to sample preparation from 
published validated methods.
Liquid-liquid extraction
1. One mL of sample (blood, urine, liver and gastric contents) was combined 
with 2 mL of deionized (DI) water and vortex mixed. The sample was made 
alkaline with the addition of 1 mL of concentrated ammonium hydroxide (28-30%) 
followed by vortex mixing and the addition of 6 mL of 1-chlorobutane. The sample 
was subsequently mixed for 10 minutes, followed by centrifugation and the addi-
tion of 200 mg of sodium sulfate to suppress emulsion formation, followed by 
another centrifugation step. The organic layer was transferred to a new tube fol-
lowed by the addition of 2 mL of 1.0 M hydrochloric acid. After mixing for 
10 minutes, the organic layer was aspirated to waste and the aqueous layer was 
made alkaline with 1 mL of concentrated ammonium hydroxide. The sample was 
vortex mixed and 3 mL of 1-chlorobutane was added followed by 10 minutes of 
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mixing and subsequently transferring the organic layer to a new tube. The method 
was applied to cases containing butyrylfentanyl and acetylfentanyl [63].
2. One mL of sample (blood) was made basic by the addition of 300 µL of tris 
buffer (pH 11) and extracted into 500 µL of ethyl acetate in a vortex mixer. The 
sample was centrifuged and the organic layer was transferred to a new tube followed 
by the addition of 75 µL of ammonium acetate (10 mM, 0.1% formic acid, pH 3.2) 
prior to evaporation. 75 µL of acetonitrile was added to the residue followed by 
5 minutes of sonication and centrifugation. The method was applied to cases  containing 
3-methylfentanyl [64]. 
3. Five hundred µL of sample (plasma or urine) was combined with 500 µL of 
an aqueous potassium carbonate solution (pH 12.3) and the sample was vortex 
mixed. 7 mL of n-hexane and ethyl acetate (7:3) was subsequently added, followed 
by mixing for 15 minutes, centrifugation, and transfer of the organic layer for 
analysis with GC-MS [65]. 
4. One mL of sample (blood, urine or vitreous humour) or 1 gram of a 1:4 tissue 
homogenate was extracted using n-butyl chloride and ammonium hydroxide with an 
acidic back extraction. The method was specifically targeted to acetylfentanyl [66]. 
Solid phase extraction
1. Five hundred µL of sample (blood) was pretreated with 2 mL of 0.1 M 
phosphate buffer (pH 6) and centrifuged. A reverse phase and ion exchange column 
(130 mg) was conditioned with 3 mL methanol, 3 mL deionized water (DI) and 
1 mL phosphate buffer. After the sample was applied, the column was washed 
with 1.5 mL DI water, 0.5 mL 0.1M acetic acid and 1.5 mL methanol. The sample 
was eluted with 2 mL of ethyl acetate, acetonitrile and ammonium hydroxide 
(78:20:2) and dried to completion at 40°C. The method was used to detect U-47700 
(3,4-dichloro-N-((1S,2S)-2-(dimethylamino)cyclohexyl)-N-methylbenzamide) and 
furanylfentanyl [67]. 
2. Five hundred µL of sample (blood or urine) was pretreated with 2 mL of potas-
sium phosphate buffer (pH 6) followed by 15 minutes of sonication, and centrifuga-
tion for 10 minutes. A Cerex Trace B (Tecan®, Männedorf, Switzerland) column 
(35 mg) was treated with 1 mL of methanol followed by 1 mL phosphate buffer. 
After the sample was applied, the column was washed with 2 mL of DI water and 
2 mL 100mM acetic acid, followed by drying and subsequent washes with 1 mL 
methanol and 1 mL ethyl acetate. The sample was eluted with 1.2 mL of ethyl acetate, 
methanol and ammonium hydroxide (93:5:2) in 600 µL aliquots. The method was 
suitable for 16 opioid compounds, including para-methoxybutyrylfentanyl, acetyl-
fentanyl, butyrylfentanyl, carfentanil, despropionylfentanyl, fentanyl,  furanylfentanyl, 
isobutyrylfentanyl N-desmethyl-U-47700, norfentanyl, para- chlorofentanyl, para-
fluorobutyrylfentanyl, para-fluoroisobutyrylfentanyl, U-47700, valerylfentanyl, and 
beta-hydroxythiofentanyl [68].
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3. One mL of sample (blood) was pretreated with 2 mL of 0.1M phosphate buffer 
(pH 6) followed by vortex mixing and centrifugation. A solid phase column was 
conditioned with 3 mL of methylene chloride, isopropanol, ammonium hydroxide 
(78:20:2), 3 mL of methanol, 3 mL of DI water and 1 mL of phosphate buffer. 
After application of the sample, the column was washed with 3 mL of DI water, 
1 mL of 1.0 M acetic acid, 2 mL of hexane, and 3 mL of methanol. The sample 
was eluted with 3 mL of methylene chloride, isopropanol, ammonium hydroxide 
(78:20:2) and dried to completion at 40°C. The method was applied to fentanyl-
positive cases [19]. 
5.5  Gas chromatography/mass spectrometry 
screening (GC/MS)
The following is an example of a screening method for common drugs of abuse 
including, fentanyl, sufentanil, alfentanil and norfentanyl in urine using an Agilent 
7890 Gas Chromatograph coupled to an Agilent 5975A mass spectrometer (Agilent 
Technologies, Santa Clara, California, United States). The limits of detection were 
2 ng/mL for alfentanil and 5 ng/mL for fentanyl and sufentanil, and mass spectra 
information is provided in table 5 [69]. 
GC-MS operating conditions
GC oven conditions: 140°C for 0.4 minutes, increased to 280°C at a rate of 
35°C/min, then 118°C/min to 320°C and held for 
1.5 minutes, (total time, 6.2 min) 
Column: 5% phenylmethylpolysiloxane (J&W DB-5), 10 m X 
0.18 mm. i.d., 0.18 μm film thickness
Injection parameters: Splitless mode 
Injector temp: 270 °C
Carrier gas: Helium, flow rate: 0.7 mL/min
Detector: Ionization mode: Electron impact (EI) mode, 70 eV
Scan parameters: SIM/SCAN mode (m/z 51-550)
Limit of detection: 2 ng/mL for alfentanil
5 ng/mL for fentanyl and sufentanil
Note that GC/MS methods typically have detection limits in the 1-10 ng/mL range 
for fentanyl and its metabolites and analogues, which are typically too high to detect 
toxicologically significant concentrations of the more potent compounds, and are not 
recommended when alternatives are available. 
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Table 5.  Characteristic mass spectral ions and retention times for selected 
fentanyls 
Substance Retention time (min) Characteristic ions (m/z)
Fentanyl-D5 4.798 250, 194
Norfentanyl-TMS 3.230 155, 154, 247, 289, 304
Fentanyl 4.800 245, 146, 189, 202
Sufentanil 4.927 140, 187, 238, 289
Alfentanil 5.185 289, 222, 268, 359
5.6  Liquid chromatography/high-resolution mass 
spectrometry (LC-HRMS) screening 
The following is an example of a screening method using a Thermo Scientific 
Dionex Ultimate 3000 RSLC ultra-high-performance liquid chromatography (Idstein, 
Germany) coupled to a Bruker Daltonics AmaZon Speed™ ion trap mass spectrom-
eter (Bremen, Germany). The method was developed for the qualitative identification 
of 44 opioid-related compounds with a detection limit of 0.1 to 5 ng/mL for all 
analytes (mass spectral data shown in table 6) [70]. 
LC-MS operating conditions
LC:
Column: Thermo Scientific Acclaim® RSLC 120 C18 column 
(2.2 µm, 2.1 X 100 mm)
Mobile phase: (A) 2 mM ammonium formate, 0.1% formic acid, 
1% acetonitrile in water
(B) 2 mM ammonium formate, 0.1% formic acid, 
1% water in acetonitrile
Gradient: Started at 99% A, was adjusted to 1% A over 8 
minutes and then held for 3 minutes to allow for 
re-equilibration
Flow rate: 500 μL/min 
Injection volume: 5 µL
MS:
Detection and ionization mode: Positive electrospray ionization scanning mode for a 
mass range of 70-800 m/z
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Table 6.  Targeted precursor ions for selected fentanyls and opioid-related 
compounds.
Compound
Precursor ion 
(MS2)a
Precursor ion 
(MS3)b
3-Methylfentanyl 351.19 –
6-O-Acetylmorphine 328.08 –
Acetaminophen 151.91 110
Acetylfentanyl 323 188
Acetylsalicyclic acid 178.92 137
Alfentanil 417.15 –
beta-Hydroxythiofentanyl 359.22 341
Buprenorphine 468.27 –
Butyrylfentanyl 351 188
Carfentanil 395.15 335.2
Codeine 300.04 –
Desproprionyl fentanyl 281 188
Dihydrocodone 302.08 –
EDDP 278.03 –
Fentanyl 337.16 –
Furanylfentanyl 375 188
Heroin 370.14 –
Hydrocodone 300.08 –
Hydromorphone 285.99 –
Ibuprofen 206.95 207
Meperidine 248.02 –
Methadone 310.1 265
Mitragynine 399.19 238
Morphine 286 –
Naloxone 328.1 310
Naltrexone 342.04 324
Naproxen 230.89 184.8
N-Desmethyltramadol 250 232
Norbuprenorphine 414.4 –
Norcodeine 286.03 –
Norfentanyl 233.07 –
Normorphine 271.96 –
Noroxycodone 302.12 284
Noscapine 414 220
O-Desmethyltramadol 250 232
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Oxycodone 316.1 298
Oxymorphone 301.97 284
para-Fluorobutyrylfentanyl 369 188
para-Fluoroisobutyrylfentanyl 369 188
Salicylic acid 136.96 93.2
Sufentanil 387.1 –
Tramadol 264 246
U-47700 329 284
W-18 422 273
a parent ion targeted for MS2, b parent ion targeted for MS3
5.7  Targeted analysis/confirmatory and 
quantitative methods
Liquid chromatography with UV detection (HPLC/UV)
No published methods using this platform are considered to be suitable for the 
detection of even toxic concentrations of fentanyl and its analogues, and HPLC/UV 
should not be used for toxicological applications.
Gas chromatography mass spectrometry (GC/MS)
The following is an example of a method using an Agilent 6890 GC coupled to a 
5973 mass spectrometer (Agilent Technologies, Santa Clara, California, United 
States). The linear range for the method was 0.5-50 ng/mL with limits of detection 
at 0.08 ng/mL for all compounds with the exception of alfentanil at 0.04 ng/mL. 
The retention time and mass spectral information is shown in table 7 [55]. 
GC-MS operating conditions
GC oven conditions: 100°C for 1 minute, increased to 200°C at a rate of 
42°C/min, then 15°C/min to 280°C and held for 
12 minutes,
Column: 5% phenylmethylsilicone (J&W DB-5), 30m X 0.25 mm. 
i.d., 0.5 mm film thickness
Injection parameters: Splitless mode 
 Injector temp: 270 °C
Carrier gas: Helium, flow rate: 0.7 mL/min
Detector: Ionization mode: EI mode: 70 eV
 Scan parameters: SIM mode
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Table 7.  Retention times and mass spectral ions used for targeted identification 
and quantification of selected fentanyl compounds
Compound
Retention time 
(mins)
Ions (m/z) (ions in bold used for 
quantification)
Norfentanyl (pentafluoropropionic) 12.8 150, 322, 229
Fentanyl 17.7 245, 146, 189
Sufentanil 18.5 289, 140, 187
Alfentanil 21.1 289, 222, 268
Fentanyl-D5 17.7 250, 151, 194
A.  Example of a method using an Agilent 7890 gas chromatograph coupled to a 
5975 mass spectrometer (Agilent Technologies, California, United States). 
Chromatographic separation was achieved using a Zebron ZB5-MS (15 m X 
0.25 mm X 0.25 µm; Phenomenex, Torrance, California, United States) capil-
lary column. The injection port was 250°C in splitless mode. The temperature 
programme was as follows: 100°C ramped at 20°C/minute until 290°C and 
held for 2 minutes. The mass spectrometer was operated in SIM mode for 
butyryl fentanyl. The linear range was 10-250 ng/mL with a limit of detection 
at approximately 2 ng/mL [63]. 
B.  Example of a method using an Agilent 6890 gas chromatograph coupled to a 
5973 mass spectrometer (Agilent Technologies, California, United States). 
Chromatographic separation was achieved using a RTX ms-1 column (15 m X 
250 µm X 0.25 mm; Restek, Bellefonte, Pennsylvania, United States). The 
injection port was set to 250°C in splitless mode. The oven temperature 
 programme was as follows: 100°C to 280°C at 20°C/minute, which was held 
for 1 minute, resulting in a 10 minute run time. The mass spectrometer was 
operated in SIM mode for acetylfentanyl. The linear range of the method was 
125-2000 ng/mL with a limit of detection at 62.5 ng/mL [66]. 
As noted below, toxicologically significant effects of fentanyl and its analogues 
occur at concentrations below 1 ng/mL, so if a laboratory only has access to GC-MS 
technology, it would be essential for it to establish its own limits of detection and 
ensure that they are appropriate for the intended purpose of analysis.
Liquid chromatography tandem mass spectrometry (LC/MS/MS)
The following is an example of method using an Alliance® HT 2705 LC system 
coupled to a Quattro Premier mass spectrometer (Waters, Massachusetts, United 
States). The mass spectrometer was operated with positive electrospray ionization 
in multiple reaction monitoring (MRM) mode for fentanyl, norfentanyl, alfentanil, 
remifentanil, sufentanil and 3-methylfentanyl (see table 8) and the method had a 
linear range from 0.1-50 ng/mL [65]. 
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LC-MS operating conditions
LC:
Column: Xterra® MS C18 column (3.5 µm, 2.1 X 150 mm) and Xterra® MS 
C18 column guard (3.5 µm, 2.1 X 10 mm) (both Waters Corpora-
tion) set to 60°C 
Mobile phase: (A) 0.15% formic acid in water
(B) 0.15% formic acid in acetonitrile
Gradient: Gradient started at 10% B at 0.00 minutes, and was increased to 
27% B over 0.50 minutes, held for 8 minutes, and  
returned to starting conditions within 0.10 minute. 
Column allowed to equilibrate for 5 minutes (total run sample, 
13.5 min) 
Flow rate: 0.3 mL/min 
MS:
Detection: Ionization mode: Positive electrospray ionization
Scan parameters: Multiple reaction monitoring (MRM) mode
Linear range 0.1-50 ng/mL
Table 8.  MRM transitions, MS conditions and retention times for the targeted 
identification and quantification of selected fentanyl compounds. (q) 
indicates ion used for quantification.
Compound Parent ion 
(m/z)
Product ion 
(m/z)
Cone volts 
(V)
Collision 
energy (eV)
Retention 
time (min)
Alfentanil 417.3 268.6 (q)
197.7
30
30
20
20
4.93
Fentanyl 337.2 188.5 (q)
105.6
35
35
25
35
4.87
Sufentanil 387.6 238.2 (q)
355.7
30
30
20
20
6.72
3-Methylfentanyl 351.5 202.4 (q)
105.6
40
40
25
35
5.70
Remifentanil 377.1 317.0 (q)
345
25
25
15
15
4.05
Norfentanyl 233 84.0 (q)
176
25
25
20
15
3.61
Fentanyl-D5 342.2 188.5 (q)
105.6
35
35
35
35
4.84
Norfentanyl-D5 238 84.0 (q)
181.9
25
25
20
15
3.59
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A.  Example of a method using an Agilent 1260 liquid chromatograph system coupled 
to a 6460 tandem mass spectrometer (Agilent Technologies). Chromatographic 
separation was achieved using a Poroshell 120 EC-C18 analytical column (2.7 µm, 
2.1 X 100 mm) set to 40°C, using 5mM ammonium formate and 0.1% formic 
acid in water (A) and acetonitrile with 0.1% formic acid (B). The gradient started 
at 20% B at 0.00 minutes, was held for 0.5 minutes and then increased to 55% 
B at 8 minutes, followed by an increase to 90% B at 8.50 minutes. The column 
was allowed to equilibrate for 3 minutes, resulting in 11.50-minute run time. The 
mass spectrometer was operated in positive electrospray ionization and in (MRM) 
mode. The method was developed for 16 novel opioid compounds (4-methoxy-
butyrylfentanyl, acetylfentanyl, butyrylfentanyl, carfentanil, despropionylfentanyl, 
fentanyl, furanylfentanyl, isobutyrylfentanyl, N-desmethyl U-47700, norfentanyl, 
para-chlorofentanyl, para-fluorobutyrylfentanyl, para-fluoroiso butyrylfentanyl, 
U-47700, valerylfentanyl, beta-hydroxythiofentanyl) and had limits of detection 
ranging from 0.01 to 0.5 ng/mL in blood and urine [68]. 
B.  Example of a method using an Agilent 1100 series high performance liquid 
 chromatograph coupled to a 6430 tandem mass spectrometer (Agilent, California, 
United States). Chromatographic separation was achieved using a ZORBAX 
Eclipse Plus C18 column (3.5 μm, 4.6 x 100 mm; Agilent, California, United 
States) operated at 40°C, using 0.1% formic acid in water (A) and 0.1% formic 
acid in methanol (B). The gradient started at 40% B adjusting to 10% B over five 
minutes and returning to 40% B at 5.5 minutes with a total run time of 10 minutes. 
The mass spectrometer was operated in positive electrospray ionization and MRM 
mode for U-47700, U-50488 (rel-3,4-dichloro-N-methyl-N-[(1R,2R)-2-(1-pyrro-
lidinyl)cyclohexyl]-benzeneacetamide) and furanylfentanyl with a linear range of 
5-500 ng/mL for U-47700 and U-50488 and 1-100 ng/mL for furanylfentanyl. 
The limit of detection was 0.5 ng/mL for all compounds [67]. 
Liquid chromatography/high-resolution mass spectrometry
Analyses were performed on a Waters Acquity I class UPLC coupled to Waters 
G2-S Q-TOF (Waters, Milford, United States). Chromatographic separation was 
achieved using an Acquity BEH C18 UPLC column (1.7 μm, 2.1 x 100 mm; Waters, 
Milford, United States) operated at 50°C 0.1% formic acid in water (A) and 0.1% 
formic acid in acetonitrile (B). The gradient started at 5% B, was held there for 1 
minute, and increased to 15% B at 6 minutes, Subsequently, the gradient was increased 
to 100% B at 7 minutes, held isocratically from 7 to 7.8 minutes and then returned 
to initial conditions over 0.1 minute with a total run time of 10 minutes. The mass 
spectrometer operated in MSE mode with the quadrupole in scanning mode and switch-
ing between low collision energy (6 eV) for full scan data and a collision energy 
ramp from 15 to 30 eV for fragmentation data. The limit of quantitation and limit of 
detection were 0.104 ng/mL and 0.031 ng/mL for fentanyl and 0.037 ng/mL and 0.011 
ng/mL for norfentanyl, respectively [71]. 
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6.  Reference data for the 
interpretation of toxicological 
findings of fentanyl and  
selected analogues
6.1 Fentanyl
Numerous incidents of fentanyl-related fatalities have been reported, with blood fentanyl 
concentrations ranging from 3.0-28 ng/mL; in comparison, recommended serum con-
centrations range from 1-2 ng/mL for analgesia and 10-20 ng/mL for anaesthesia [26,56]. 
Case series of reported fentanyl concentrations in adults who died from transdermal, 
intravenous, and oral abuse of fentanyl patches were 18 ng/mL (range 4-54), 59 (3-383) 
and 28 (7-97), respectively [29,72]. In fentanyl-only related deaths, average blood con-
centrations have been increasing, with a 2003 case series reporting an average result of 
9 ng/mL [73], and a 2014 case series reporting an average of 30 ng/mL [74]. A cluster 
of 9 fentanyl-laced heroin deaths were reported in Australia with reported average and 
median femoral blood concentrations of 18 and 29 ng/mL (range <1-45) accompanied 
by morphine, 140 and 80 ng/mL (range 20-400 ng/mL) [75]. The combination of heroin 
and fentanyl has become a routine toxicological finding in suspected opioid overdose 
death investigations, but even fentanyl by itself is posing an increased risk of overdose 
and death to recreational users.
6.2 3-Methylfentanyl and alpha-methylfentanyl
Deaths and intoxications attributed to 3-methylfentanyl and alpha-methylfentanyl were 
reported in the late 1970s to 1980s. Emergency physicians in the United States became 
suspicious of “China White” after an unusual increase in narcotic overdoses appearing 
in the emergency department (ED) coupled with “routine drugs of abuse” screens pre-
senting negative for opiates despite reversal of effects by naloxone [76,77]. The causal 
agent for those cases was analytically confirmed to be 3-methylfentanyl, but another 15 
deaths were caused by alpha-methylfentanyl [78]. In 122 fentanyl-related deaths during 
the 1980s, the average concentration of fentanyls found in blood (including fentanyl, 
alpha-methylfentanyl, and 3-methylfentanyl) was 3.0 +/- 3.1 ng/mL [79]. Although this 
range appears to be consistent with concentrations recommended in serum for 
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management of analgesia using fentanyl, this average includes findings of alpha-meth-
ylfentanyl and (+) 3-methylfentanyl, which are both more potent by a factor of 1.1 and 
16 respectively than fentanyl [79,80]. Concentrations of alpha- methylfentanyl in reported 
fatalities averaged 7 ng/mL (2-11) [56]. More than 110 3-methylfentanyl fatalities were 
reported in 2005-2006 in Estonia where the mean combined concentration of cis and 
trans isomers among cases was 1.9 ng/mL, which is 10 times lower than the mean 
fentanyl concentration in fentanyl-related fatalities [81]. For cases only involving 3-meth-
ylfentanyl, cis-3-methylfentanyl ranged from 0.06-2.59 (n=50) and trans- ranged from 
0.19-1.91 (n=49). In deaths involving 3-methylfentanyl in Cuyahoga County, Ohio, 
United States in 2016, concentrations were in the range of 0.15-1.7 ng/mL [82].
6.3 Acetylfentanyl
Acetylfentanyl gained popularity in the United States in 2013 after 14 reported 
deaths in Rhode Island; subsequently reports of acetylfentanyl related overdose 
fatalities were reported in Pennsylvania, California, Louisiana, North Carolina, and 
Oregon [83,84]. Forty-one acetylfentanyl-related overdose deaths in Pennsylvania 
reported blood concentrations with median and mean of 11 and 169 ng/mL, (range 
0.13-2100 ng/mL); all but one case was ruled as multiple drug toxicity (acetylfen-
tanyl in blood = 170 ng/mL) with fentanyl itself being detected in 26 cases and 
heroin in 22 [85]. Peripheral blood acetylfentanyl concentrations reported in four 
cases were 310-600 ng/mL when acetylfentanyl was the only drug present, and 
6-12 ng/mL when fentanyl concentrations were 15-21 ng/mL (n=3) [86].  Acetylfentanyl 
was confirmed in a series of non-fatal intoxications presenting to the ED in Sweden 
between April and November 2015; serum concentrations (n=7) ranged from 
 0.6-51.6  ng/mL [10]. In Europe, acetylfentanyl was confirmed in 1 death in 2013, 
2 in 2014, and 29 in 2015; in 19 of the deaths, acetylfentanyl was the cause of or 
contributor to death [87]. 
6.4 Butyrylfentanyl
Butyrylfentanyl was first reported by the Early Warning System operated by the 
EMCDDA and Europol from seizures in Poland in summer 2013, before its appear-
ance in the United States in 2014 [12]. Sweden reported its first seizures in April 2014; 
two intoxications presenting to the emergency department had serum concentrations 
of 0.9 and 0.6 ng/mL, with concomitant fentanyl concentrations of 4.3 and 10.2 ng/
mL [12]. An intoxication with butyrylfentanyl in the United States involved an 18 y/o 
M who survived an overdose but who suffered from clinically significant hemoptysis, 
acute lung injury, hypoxic respiratory failure, and diffuse alveolar hemorrhage after 
snorting a white powder; which was subsequently identified as butyrylfentanyl by gas 
chromatography and mass spectrometry [88]. Butyrylfentanyl may undergo  postmortem 
redistribution, based on analysis of butyrylfentanyl in multiple specimens, including 
paired cardiac and peripheral blood samples; peripheral blood results ranging from 
3.7-99 ng/mL in 4 deaths [50,63,89].
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6.5 Furanylfentanyl
In 2016, Helander et. al. reported furanylfentanyl serum concentrations of 4.4-148 ng/
mL in non-lethal intoxications presenting to the ED, however, survival of furanylfen-
tanyl intoxication in these cases may be attributed to prompt treatment and respiratory 
support, as these antemortem concentrations overlap with those seen in deaths [10]. 
Furanylfentanyl was confirmed in eight postmortem cases with blood concentrations 
ranging from 2.5-76 ng/mL (mean and median; 26 + 28 and 12.9 ng/mL, respectively) 
[67]. Over the course of four months in 2015 and 2016, a cluster of seven fatal 
intoxications involving furanylfentanyl occurred in Sweden, where furanylfentanyl 
intoxication, either alone or in combination with other substances, was determined to 
be the cause of death with concentrations ranging from 0.43-2.89 ng/mL. [90]. 
6.6 Carfentanil
Carfentanil was identified in drug seizures in Latvia in 2013 [91]. In July 2016, 
carfentanil emerged on the recreational drug scene in combination with heroin in 
the United States. It has subsequently been implicated in a large number of overdoses 
and deaths. The first reports were in Michigan, Ohio and Florida. In Northeast Ohio, 
there were over 25 deaths within a 30-day period attributed to carfentanil; between 
two state counties there were 165 reported deaths from carfentanil alone or in com-
bination with heroin and fentanyl [82]. Carfentanil blood concentrations were in the 
range between 0.11-0.88 ng/mL. When approximately 500 postmortem cases were 
submitted for analysis at Miami-Dade County Medical Examiner’s Office in a 
 six-month period, 134 cases were positive for carfentanil, and of those, 104 were 
initially missed by gas chromatography mass spectrometry [70]. In a four-month 
span in the last half of 2016, carfentanil was identified in 262 postmortem blood 
specimens, with mean and median concentrations of 0.193 and 0.098 ng/mL (range 
0.010 to 2.0) [92]. Carfentanil has also been reported in impaired driving cases; 
six cases were reported out of West Palm Beach, Florida, with concentrations rang-
ing from 0.0115-0.125 ng/mL in blood [93]. Other non-fatal intoxications (n=1) and 
impaired driving cases (n=2) had serum and blood results of 0.6 and 0.013-0.043 ng/
mL [94,95]. These reports of carfentanil detection in the United States are some of 
the first reports in literature of carfentanil being intentionally sold for recreational 
abuse; the only previous report was an accidental exposure during an attempt to 
tranquilize large animals [96]. 
6.7 Acrylfentanyl
Acrylfentanyl followed the emergence of carfentanil and furanylfentanyl; its first 
reported identification in literature was in Denmark in May 2016 [97]. Acrylfentanyl 
has been detected in at least 20 non-fatal intoxications; in eight of those cases, 
acrylfentanyl was confirmed in serum (0.5-2.1 ng/mL) [15]. Between April and 
40 Identification and analysis of fentanyl and its analogues in biological specimens
October 2016, a series of 40 lethal intoxications occurred in Sweden, in which the 
presence of acrylfentanyl was determined to be the main, or a contributing cause 
of death; concentrations ranged from 0.01-5.27 ng/mL [98]. Of those 40 cases, only 
two involved acrylfentanyl as the sole intoxicant and acrylfentanyl was confirmed 
at 0.01 and 0.02 ng/mL. In 2016, a total of 47 analytically confirmed deaths associ-
ated with acrylfentanyl occurred in Europe; Sweden accounted for 43 of those cases, 
but Denmark (n=1) and Estonia (n=3) also reported deaths. In addition to the three 
listed countries, Finland, Latvia and Slovenia have also reported detections of 
acrylfentanyl [36]. 
6.8 Other fentanyl analogues
Besides the compounds described above, there have been sporadic reports of several 
other fentanyl analogues, including para-fluorobutyrylfentanyl, para-fluoroiso-
butyrylfentanyl, para-methoxybutyrylfentanyl, ortho-fluorofentanyl and ocfentanil. 
Specific case reports for these analytes, as well as for previously listed compounds, 
are listed in annex 1. Several new fentanyl analogues have appeared in 2015 and 
2016. The Miami-Dade County Medical Examiner Office reported the detection of 
new related compounds between 2015 and 2016, including beta-hydroxythiofentanyl 
(n=9), para-fluoroisobutyrylfentanyl (n=22), and U-47700 (n=4) [2]. Fatal  intoxications 
with fentanyl analogues in Sweden between 2015 and 2016 primarily involved acetyl-
fentanyl (n=34) and acrylfentanyl (n=43); in addition, para-fluoroisobutyrylfentanyl 
(n=14), furanylfentanyl (n=10), para-chloroisobutyrylfentanyl (n=3), tetrahydrofuran-
fentanyl (n=5), para-methoxybutyrylfentanyl (n=2), para-fluorobutyrylfentanyl (n=1) 
and butyrylfentanyl (n=1) have also been reported [4]. 
Fentanyl and its analogues have been detected in hospitalizations, impaired drivers, 
and in death investigation casework. The triad of opioid symptoms, CNS depression, 
miotic pupils, and respiratory depression are common clinical signs seen in cases 
presenting to EDs. Additionally, signs of intoxication (drowsiness, inattention, slowed 
reflexes) leading to cognitive and psychomotor impairment have been documented. 
The impairing effects of opioids can also be exacerbated when combined with other 
CNS depressants such as alcohol or benzodiazepines. Fentanyl and its analogues 
should be considered by hospital staff, emergency responders, medical examiners, 
death investigators and police officers when investigating suspected opioid intoxica-
tions, especially when hospital immunoassay-based tests are negative, or presumptive 
positive results cannot be confirmed. 
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n
g
s 
w
ei
g
h
ed
 1
36
0 
g
.
B
lo
o
d
: 
0.
01
+
 E
tO
H
 
[9
8]
Te
tr
o
h
yd
ro
fu
ra
n
yl
-
fe
n
ta
n
yl
26
 y
/o
 M
 t
ak
en
 t
o
 E
D
 a
ft
er
 
in
tr
an
as
al
 a
p
p
lic
at
io
n
 o
f 
“f
en
ta
n
yl
” 
n
as
al
 s
p
ra
y.
D
ec
re
as
in
g
 c
o
n
sc
io
u
sn
es
s,
 m
io
ti
c 
p
u
p
ils
, 
an
d
 r
es
p
ir
at
o
ry
 d
ep
re
s-
si
o
n
. 
N
al
o
xo
n
e 
ad
m
in
is
te
re
d
.
Se
ru
m
: 
45
U
ri
n
e:
 1
36
+
 fl
u
n
it
ra
zo
la
m
[1
1]
 
A
bb
re
vi
at
io
ns
 i
n 
an
ne
x
 
 E
D
 =
 E
m
er
ge
nc
y 
D
ep
ar
tm
en
t, 
E
M
S 
= 
E
m
er
ge
nc
y 
M
an
ag
em
en
t 
Se
rv
ic
es
, 
IC
U
 =
 I
nt
en
si
ve
 C
ar
e 
U
ni
t, 
H
x 
= 
H
is
to
ry
, 
4-
O
H
-a
lp
ra
zo
la
m
 =
 H
yd
ro
xy
-a
lp
ra
zo
la
m
, 
N
PS
 
= 
N
ew
 P
sy
ch
oa
ct
iv
e 
Su
bs
ta
nc
es
, 
IV
 =
 i
nt
ra
ve
no
us
, 
SC
 =
 s
ub
cu
ta
ne
ou
s,
 E
tO
H
 =
 E
th
an
ol
, 
7-
A
M
C
 =
 7
-a
m
in
o 
cl
on
az
ep
am
, 
6-
M
A
M
 =
 6
-m
on
oa
ce
ty
lm
or
ph
in
e,
 2
-A
I 
= 
2-
am
in
oi
nd
an
e,
 M
D
PV
 =
 m
et
hy
le
ne
di
ox
yp
yr
ov
al
er
on
e,
 P
V
 =
 p
yr
ov
al
er
on
e,
 2
C
-P
 =
 2
,5
-d
im
et
ho
xy
-4
-(
n)
-p
ro
py
lp
he
ne
th
yl
am
in
e,
 5
-E
A
PB
 =
 1
-(
be
nz
of
ur
an
-5
-y
l)
-N
-
et
hy
lp
ro
pa
n-
2-
am
in
e,
 4
-F
M
C
= 
4-
flu
or
om
et
hc
at
hi
no
ne
/fl
ep
he
dr
on
e,
 4
F-
PV
8 
= 
4-
flu
or
o-
al
ph
a-
py
rr
ol
id
in
oh
ep
tio
ph
en
on
e,
 a
lp
ha
-P
V
T
 =
 a
lp
ha
-p
yr
ro
lid
in
op
en
tio
th
io
ph
e-
no
ne
, 
M
D
PH
P 
= 
al
ph
a-
py
rr
ol
id
in
oh
ep
ta
no
ph
en
on
e,
 
4-
M
eO
-P
V
8 
= 
1-
(4
-m
et
ho
xy
ph
en
yl
)-
2-
(p
yr
ro
lid
in
-1
-y
l)
-h
ep
ta
n-
1-
on
e,
 
3-
M
eO
-P
C
P/
4-
M
eO
-P
C
P 
=
 
3-
m
et
ho
xy
ph
en
cy
cl
id
in
e/
4-
m
et
ho
xy
ph
en
cy
cl
id
in
e,
 a
lp
ha
-P
B
P 
= 
al
ph
a-
py
rr
ol
id
in
ob
ut
io
ph
en
on
e,
 a
lp
ha
-P
PP
 =
 a
lp
ha
-p
yr
ro
lid
in
op
ro
pi
op
he
no
ne
, 
4F
-P
V
P 
= 
4-
flu
or
o-
py
rr
ol
id
in
ov
al
er
op
he
no
ne
, B
Z
E
 =
 b
en
zo
yl
ec
go
ni
ne
, 3
-M
M
C
 =
 3
-m
et
hy
lm
et
hc
at
hi
no
ne
, 4
-F
M
A
 =
 4
-fl
uo
ro
m
et
ha
m
ph
et
am
in
e,
 4
F-
bu
ty
ry
lf
en
ta
ny
l 
= 
4-
flu
or
o 
bu
ty
ry
lf
en
-
ta
ny
l, 
4C
l-
al
ph
a-
PV
P 
= 
4-
ch
lo
ro
-a
lp
ha
-p
yr
ro
lid
io
no
va
le
ro
ph
en
on
e,
 G
H
B
 =
 g
am
m
a-
hy
dr
ox
yb
ut
yr
ic
 a
ci
d,
 N
PP
 =
 2
-(
is
op
ro
py
la
m
in
o)
-1
-p
he
ny
lp
en
ta
n-
1-
on
e;
 N
E
H
 =
 
N
-e
th
yl
no
rh
ex
ed
ro
ne
, 
4-
A
N
PP
 =
 4
-a
ni
lin
o-
N-
ph
en
et
hy
lp
ip
er
id
in
e,
 T
H
C
 =
 t
et
ra
hy
dr
oc
an
na
bi
no
l, 
T
H
C
C
 =
 1
1-
no
r-
ca
rb
ox
y-
de
lta
-9
-t
et
ra
hy
dr
oc
an
na
bi
no
l. 
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